Understanding resistance to targeted therapies in head and neck, breast cancer
MSN highlights University of Cincinnati Cancer Center research
MSN highlighted University of Cincinnati Cancer Center and Cincinnati Veterans Affairs Medical Center research published in the journal Oncotarget that reviewed current research on why Epidermal Growth Factor Receptor (EGFR)-targeted therapies often fail in breast and head and neck cancers.
The review, led by co-corresponding authors Vinita Takiar, MD, and Susan Waltz, PhD, offers an in-depth look at the molecular barriers to EGFR inhibition and provides insights that could inform the development of more effective and durable treatments.
EGFR is a critical protein that regulates cell growth and survival, and it is frequently overexpressed in breast and head and neck cancers. Although therapies targeting EGFR showed early promise, resistance has become a significant challenge.
The review analyzes resistance mechanisms in breast cancer including the movement of EGFR from the cell surface into the nucleus, promoting DNA repair. By analyzing these resistance mechanisms, the authors highlight combination therapies from current research that target EGFR and other key molecular pathways that may enhance treatment outcomes.
"A recent phase 1 study has shown that patients with recurrent or metastatic head and neck cancer who received BCA101, a bifunctional dual targeting drug that targets EGFR and TGF-β in combination with pembrolizumab, were able to achieve an overall response rate of 65%," the coauthors noted.
Featured photo at top of pink Breast Cancer Awareness ribbon. Photo/Lludmila Chernetska/iStock.
Related Stories
From hobbyist photographer to professional educator
October 9, 2026
DAAP alum and photographer HATSUE studied communication design after a pivot in high school from a track toward veterinary school. Today, they teach photography at 1001 Colors white working as an artist and curator in Cincinnati.
UC researcher to launch national study with $2.5 million NIH grant
October 9, 2026
A University of Cincinnati researcher has received a $2.5 million National Institutes of Health grant to conduct research during the next five years. Natalie Kreitzer, MD, a University of Cincinnati College of Medicine physician-researcher, received an R01 independent research grant from the NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development. The funding will support a test program for caregivers of patients with traumatic brain injury, as reported by the Cincinnati Business Courier.
Lighting up the skyline for Blink
October 9, 2026
A team of University of Cincinnati College-Conservatory of Music students designed “Echoes of Light,” a music-and-light installation on Ohio’s largest mural for BLINK, Cincinnati’s massive public light and art festival.